Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 05, 2015 10:30 AM ET

Pharmaceuticals

Company Overview of Teva Pharmaceuticals USA, Inc.

Company Overview

Teva Pharmaceuticals USA, Inc. manufactures and markets generic drugs in the United States. It offers generic products for various therapeutic options, such as cardiovascular, anti-infective, central nervous system, anti-inflammatory, oncolytic, anti-diabetic, analgesic, dermatologic, respiratory, and women’s health. The company offers its products in various dosage forms, such as tablets, capsules, injectables, creams, ointments, inhalants, solutions, and suspensions. It serves patients through distributors. Teva Pharmaceuticals USA, Inc. was formerly known as Lemmon Pharmacal Company and changed its name to Teva Pharmaceuticals USA, Inc. in 1996. The company was founded in 1945 and is base...

1090 Horsham Road

North Wales, PA 19454

United States

Founded in 1945

Phone:

215-591-3000

Fax:

215-591-8600

Key Executives for Teva Pharmaceuticals USA, Inc.

Chief Executive Officer of Teva North America and President of Teva North America
Age: 67
Vice President of Government Affairs
Vice President of Government Affairs
Vice President of Government Affairs
Vice President of Government Affairs
Compensation as of Fiscal Year 2015.

Teva Pharmaceuticals USA, Inc. Key Developments

VIVUS, Inc. Files Lawsuit Against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd for Infringement of Qsymia Patents

VIVUS, Inc. announced that it has filed a lawsuit in the U.S. District Court for the District of New Jersey against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd., collectively referred to as Teva. The lawsuit was filed in response to an Abbreviated New Drug Application, or ANDA, filed by Teva. In its application, Teva seeks to market and sell generic versions of the currently approved doses of Qsymia (phentermine and topiramate extended-release) capsules CIV prior to the expiration of U.S. Patents 7,056,890, 7,553,818, 7,659,256, 7,674,776, 8,580,298, 8,580,299, 8,895,057 and 8,895,058, which are listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. VIVUS filed the lawsuit on the basis that Teva's proposed generic products infringe each of these patents held by VIVUS.

TWi Pharmaceuticals Sells its Products in US Market, Originally Planned to be Sold by Teva

TWi Pharmaceuticals, Inc. announced that TWi and Teva Pharmaceuticals have reached an agreement that will transfer the United States sales and distribution rights of TWi's generic versions of Megace ES (megestrol acetate oral suspension, 625 mg/5 ml) and Lidoderm (lidocaine patch, 5%) from Teva to TWi. TWi will distribute both products through its wholly-owned subsidiary, TWi Pharmaceuticals USA.

IntelliPharmaCeutics International Inc. Signs Exclusive Licensing and Manufacturing Agreement with Teva Pharmaceuticals USA, Inc

Intellipharmaceutics International Inc. has entered into an agreement with Teva Pharmaceuticals USA, Inc. by which the Company has granted Teva an exclusive license to market in the U.S. an extended release drug product candidate for which Intellipharmaceutics currently has an abbreviated new drug application pending for U.S. Food and Drug Administration approval. Under the agreement with Teva, subject to certain conditions, Intellipharmaceutics has agreed to manufacture and supply the product exclusively for Teva and Teva has agreed that Intellipharmaceutics will be its sole supplier of the product to be marketed in the U.S. There can be no assurance as to when or if the product will be approved by the FDA or that, if so approved, it will be successfully commercialized and produce significant revenue for the Company.

Similar Private Companies By Industry

Company Name Region
Bridgesite Clinical Research United States
Nulab, Inc. United States
RHEI Pharmaceuticals, Inc. United States
Cambridge Major Laboratories, Inc. United States
Hanall Pharmaceutical International, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
March 5, 2015
Teva Pharmaceuticals, Abbreviated New Drug Application for Flecainide Acetate
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Teva Pharmaceuticals USA, Inc., please visit www.tevagenerics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.